OraCAb® is an orally administered immunotherapeutic product containing ovine polyclonal antibodies directed against recombinant fragments of Toxin A and Toxin B for the treatment of non-life threatening primary and recurrent Clostridioides difficile infections (“CDI”). OraCAb was developed in collaboration with the UK Health Security Agency (UKHSA), with which MicroPharm has a long-standing scientific collaboration.  A Phase II clinical trial is scheduled to commence in mid-2025.

Funded by Wellcome.